Argenta Discovery and Precos have formed an alliance to provide cancer drug discovery services and expertise on a fee-for-service basis.
The collaboration enables Argenta and Precos to undertake complete, integrated oncology-focused drug discovery programmes for their contract research clients, from hit finding to in vivo 'proof-of-concept'.
Dr Christopher Ashton, chief executive officer of Argenta Discovery, said: 'Argenta has partnered with Precos to provide clients with dedicated access to specialist in vitro, ex vivo and in vivo cancer models and expertise.' Professor Susan Watson, scientific director of Precos added: 'Precos is an oncology specialist in pre-clinical research and development because we offer patient-relevant in vivo models.
'These models closely reflect the clinical situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumours and metastasis.'
